Nov 27, 2019
Things get a little nerdy in this episode, which focuses on the
basic science of what makes the inflammasome tick in CAPS, as well
as data on the use of interleukin 1 inhibition.
Hint: Listen to “The Inflammasome for Dunces”
episode first, and this one will make more sense.
- Intro :20
- Recap of Part 1 :33
- Overview of this episode 1:56
- Familial cold autoinflammatory syndrome
- Muckle-Wells syndrome 6:34
- The two checkpoint problem 8:36
- What do we know about the inhibition of the inflammasome?
- Back to the trebuchet analogy
Brought to you by GSK. Considering a treatment change for
patients with active SLE? Learn about a treatment option for your
patients at treatfortodayandtomorrow.com
- A paper on CARD8 in the setting of CAPS
- Let’s talk about prostaglandins
- There are over 100 mutations in CAPS
- Let’s talk about treatment 18:42
- One caveat 25:41
- That’s CAPS 26:45
- Reach out to me via email and on Twitter
- Episode recap 27:41
We’d love to hear from you! Send your comments/questions to
Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
Brought to you by GSK. Consider the long-term impact of
disease activity, flares and corticosteroid use on patients with
active SLE. Learn more now at
Disclosure: Brown reports no relevant financial
L, et al. Immunity. 2004;20:319-325.
PA, et al. Arthritis Rheum. 2019;71:1955-1963.
C, et al. J Rheumatol. 2014;41:1721-1722.
Hawkins PN, et al. NEJM. 2003;348:2583-2584.
et al. Lancet. 2004;364:1779-1785.
Hoffman HM, et al. Clin Ther. 2012;34:2091-2103.
Ito S, et al. Arthritis Res Ther.
JB, et al. Ann Rheum Dis. 2011;70:2095-2102.
et al. NEJM. 2009;360:2416-2425.
Mamoudjy N, et al. Orphanet J Rare Dis.
Rosengren S, et al. J Allergy Clin Immunol.
et al. J Cutan Med Surg. 2008;12:8-16.
Tassi S, et
al. Proc Natl Acad Sci USA. 2010;107:9789-9794.
BD, et al. Am J Kidney Dis. 2007;49:477-481.